H. Ishii

Keunchil Park, F. de Marinis, M. Krzakowski, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Keunchil Park, F. de Marinis, M. Krzakowski, 2018, The Lancet. Oncology.

Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor

K. Ohshima, A. Kawaguchi, K. Fujimoto, 2022, Japanese Journal of Radiology.

Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy

K. Azuma, T. Hoshino, T. Kojima, 2021, Investigational New Drugs.

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.

Y. Hosomi, S. Miyamoto, N. Kikuchi, 2020, JAMA oncology.

Prognostic Value of Serum Tumor Markers in Patients With Stage III NSCLC Treated With Chemoradiotherapy

K. Azuma, T. Kinoshita, T. Hoshino, 2019, In Vivo.

Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti‐PD‐1 inhibitor

T. Kondo, K. Azuma, S. Hattori, 2018, International journal of cancer.

Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib

K. Azuma, T. Kinoshita, T. Hoshino, 2014, Oncology letters.

Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples

K. Nishio, K. Azuma, I. Okamoto, 2015, Oncotarget.

Abstract. Factors predicting the efficacy of erlotinib treatment in patients with EGFR mutation‐negative non‐small‐cell lung cancer (NSCLC) have not been well studied. This retrospective study investigates whether patient characteristics, such as site of metastasis, can predict the efficacy of erlot

K. Azuma, T. Kinoshita, T. Hoshino, 2014 .

Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study

T. Ohira, K. Nishio, K. Azuma, 2020, Cancer.

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer

Kaoru Tanaka, K. Azuma, K. Nakagawa, 2019, Thoracic cancer.

Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy

K. Azuma, T. Kinoshita, T. Hoshino, 2017, BMJ Open Respiratory Research.

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients

K. Nishio, K. Azuma, S. Hattori, 2016, Scientific Reports.

Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy

K. Azuma, T. Sasada, T. Kinoshita, 2017, Oncotarget.

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003)

K. Azuma, I. Okamoto, T. Kurata, 2022, Thoracic cancer.

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.

K. Azuma, T. Kinoshita, M. Kage, 2016, European journal of cancer.

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer

Yohei Imamura, K. Azuma, T. Kinoshita, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC

K. Azuma, T. Kinoshita, T. Hoshino, 2020, Thoracic cancer.

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision Samples

K. Azuma, I. Okamoto, M. Kage, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paired maximum inspiratory and expiratory plain chest radiographs for assessment of airflow limitation in chronic obstructive pulmonary disease.

K. Azuma, T. Kinoshita, T. Kawayama, 2015, European journal of radiology.

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases

I. Okamoto, H. Daga, T. Shimose, 2022, Cancer management and research.

Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients

K. Azuma, T. Hoshino, M. Ichiki, 2018, AntiCancer Research.

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib

K. Nishio, K. Azuma, T. Hoshino, 2020, Scientific Reports.

Predictive value of CD73 expression in EGFR-mutation positive non-small-cell lung cancer patients received immune checkpoint inhibitors.

K. Azuma, T. Kinoshita, T. Hoshino, 2018 .

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial

K. Azuma, Y. Koh, N. Yamamoto, 2023, BMC Cancer.